Breaking News Instant updates and real-time market news.

NVLS

Nivalis Therapeutics

$6.25

-0.03 (-0.48%)

07:05
11/29/16
11/29
07:05
11/29/16
07:05

Nivalis Therapeutics downgraded on lack of drug efficacy at Stifel

As noted earlier, Stifel downgraded Nivalis to Hold from Buy. Analyst Thomas Shrader downgraded the stock after the company's cavosonstat for CF did not show meaningful efficacy in a Phase II trial. Target to $3.25 from $16.

NVLS Nivalis Therapeutics
$6.25

-0.03 (-0.48%)

11/29/16
RAJA
11/29/16
DOWNGRADE
RAJA
Market Perform
Nivalis Therapeutics downgraded to Market Perform Raymond James
Raymond James analyst Christopher Raymond downgraded Nivalis Therapeutics to Market Perform from Outperform following cavasonstat's SNO-6 miss and the halt of further development in F508del homozygotes.
11/29/16
STFL
11/29/16
DOWNGRADE
STFL
Hold
Nivalis Therapeutics downgraded to Hold from Buy at Stifel
11/29/16
COWN
11/29/16
DOWNGRADE
COWN
Market Perform
Nivalis Therapeutics downgraded to Market Perform from Outperform at Cowen
11/29/16
BARD
11/29/16
DOWNGRADE
BARD
Neutral
Nivalis Therapeutics downgraded to Neutral from Outperform at Baird

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.